KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Operating Income (2016 - 2025)

Eli Lilly's Operating Income history spans 17 years, with the latest figure at $8.9 billion for Q4 2025.

  • For Q4 2025, Operating Income rose 66.8% year-over-year to $8.9 billion; the TTM value through Dec 2025 reached $29.2 billion, up 80.56%, while the annual FY2025 figure was $29.2 billion, 80.56% up from the prior year.
  • Operating Income reached $8.9 billion in Q4 2025 per LLY's latest filing, up from $8.0 billion in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $8.9 billion in Q4 2025 to a low of $1.4 billion in Q2 2021.
  • Average Operating Income over 5 years is $3.6 billion, with a median of $2.6 billion recorded in 2022.
  • Peak YoY movement for Operating Income: tumbled 37.78% in 2023, then skyrocketed 101.06% in 2025.
  • A 5-year view of Operating Income shows it stood at $2.4 billion in 2021, then fell by 11.82% to $2.1 billion in 2022, then surged by 44.94% to $3.0 billion in 2023, then soared by 77.35% to $5.3 billion in 2024, then surged by 66.8% to $8.9 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Operating Income are $8.9 billion (Q4 2025), $8.0 billion (Q3 2025), and $7.0 billion (Q2 2025).